Introduction {#s0001}
============

Clinical research trials sponsored by the pharmaceutical industry have profound impacts on the practice of medicine.[@cit0001] The industry can support a number of trials at all stages of a product's life with significant financial investment assigned to the innovation.[@cit0002] Therefore, there is potential for considerable monetary loss if the results and conclusions of these trials are unfavourable for the sponsor.[@cit0001],[@cit0003] A number of systematic reviews have documented industry sponsorship of drug studies to be associated with findings favourable to the sponsor.[@cit0004]--[@cit0008] More recently, a review written by the Cochrane Collaboration found there to be less correspondence between the results and conclusions of industry-funded studies when compared to non-industry-funded studies.[@cit0001]

In an era of rapidly developing therapies, physicians often rely on the peer-reviewed literature -- especially the abstracts of published studies -- to remain well informed about their respective fields of practice. It is therefore of paramount importance to evaluate outcome reporting bias in study abstracts. This was assessed in the ophthalmic literature by Alasbali and colleagues, who found industry-funded studies on the ocular hypotensive efficacy of topical prostaglandin analogues to be more likely to report proindustry abstract conclusions, which often did not correspond with studies' results.[@cit0009] Our group performed a similar analysis of randomized clinical trials on the efficacy of intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy for retinal vein occlusion published in high-impact journals and did not find industry-sponsorship to be associated with an increased rate of reporting bias.[@cit0010] The focus on high-impact journals allowed the authors to capture journals that were most likely to be referred to by physicians, and the results of this study were reassuring given the rapid adoption of anti-VEGF therapy for a number of ocular conditions.

Treatment of diabetic macular edema (DME) remains controversial among vitreoretinal specialists.[@cit0011],[@cit0012] Given the increased recognition of the role of inflammation in the development of DME, intravitreal corticosteroid therapy has been shown to provide promising anatomical and visual benefits, especially when compared to laser therapy.[@cit0013]--[@cit0015] Compared to anti-VEGF therapy, intraocular corticosteroids do carry class-specific risks such as cataract progression and ocular hypertension that theoretically could be downplayed in abstract presentation.[@cit0015] The purpose of this study was to examine the relationship between industry funding and the presence of spin in high-impact studies assessing the efficacy and safety of intravitreal corticosteroid therapy for DME.

Methods {#s0002}
=======

This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.[@cit0016] Approval from an Institutional Review Board was not required for this study as no human subjects were involved, and analysis was based upon information from published literature.

Search Methods {#s0002-s2001}
--------------

Ovid Medline and Ovid Embase were searched from inception through July 16, 2018, for studies investigating the treatment of patients with diabetic macular edema with intravitreal corticosteroid therapy (ie, triamcinolone, fluocinolone, or dexamethasone) used in at least one of their treatment arms. The search strategy ([[Appendix 1](https://www.dovepress.com/get_supplementary_file.php?f=262085.pdf)]{.ul}) was designed to generate studies published in English journals with an IF greater than 2 as per the Clarivate Analytics 2017 Journal Citation Report.[@cit0017] The inclusion of studies published in journals with IF greater than 2 is presumed to reflect studies more likely to be read by clinicians when browsing recent medical literature.

Study Selection {#s0002-s2002}
---------------

Search results were imported into DistillerSR (Evidence Partners; Ottawa, Canada) to manage all identified records. Title and abstract screening was completed to select for studies that were primary RCTs and meta-analyses. Full-text screening was then completed to select for studies that reported on main outcomes of visual acuity, retinal thickness, and/or complications. Studies that published secondary or sub-analyses on previously published RCTs were excluded. [Figure 1](#f0001){ref-type="fig"} outlines the flow of study selection as per the PRISMA statement.[@cit0016]Figure 1Selection of randomized clinical trials and meta-analyses.

Data Collection and Analysis {#s0002-s2003}
----------------------------

Our methods of study evaluation and data extraction have been previously described.[@cit0010] Study quality was assessed with the scoring scale utilized by Alasbali et al (2009) and is outlined in [Table 1](#t0001){ref-type="table"}.[@cit0009] Correspondence between significance of the main outcome measure result and abstract conclusion was assessed by surveying whether the wording of the abstract conclusion matched the statistical analysis of the results as they pertained to the main outcome measure(s). Following independent data extraction, all discrepancies on the standardized data sheet were resolved by unanimous agreement amongst the authors (HN, AK, JS). One author (HN) also collected objective data on the included studies: sample size, source of funding (industry vs non-industry), whether the publication was authored by an industry employee as reported in the manuscript, and whether any of the co-authors had a potential conflict of interest (COI). The presence of a potential author COI was determined by assessing the study's disclosure statement and was defined as any previous relationship between a co-author and the company that manufactured the drug intervention(s) being studied. Corresponding authors of the included studies were contacted if any of the objective information was not evident as part of the published article.Table 1Criteria Utilized for Grading of Study Quality[@cit0009]Quality ScoreCriteria1: Meta-analysis (To assign this level, all of the following criteria must be met).1. The paper reports a comprehensive search for evidence.\
2. The authors avoid bias in selecting articles for inclusion.\
3. The authors assess each article for validity.\
4. The paper reports clear conclusions that are supported by the data and appropriate analysis.1: Large RCT (To assign this level, all of the following criteria must be met).1. Patients were randomly allocated to treatment groups.\
2. Follow-up was at least 80% complete.\
3. Both the patients and the investigators were blind to the treatment the patient received.\
4. Patients were analyzed in the treatment groups to which they were assigned.\
5. The sample size was large enough to detect the outcome of interest.2: RCTRCT or overview that did not meet level 1[^1]

The primary outcome of the present study was the association between funding source and the correspondence between the studies' abstract conclusion and statistical significance of their main outcome, expressed as an odds ratio. Exploratory secondary analyses were also performed to determine any associations between our variables of interest, including study sample size, journal impact factor and the presence of any COI. Statistical analysis included the Fisher exact test for categorical data, and the Mann--Whitney *U*-test/Kruskal--Wallis test or Student's *t*-test/one-way ANOVA for numerical data, as appropriate. A p-value \< 0.05 was considered statistically significant. All data were extracted and stored in Microsoft Excel software (Microsoft; Redmond, WA). Statistical analysis was performed using SPSS (IBM Corp; Armonk, New York; software version 22).

Results {#s0003}
=======

The original search of both databases yielded 10,073 articles, reduced to 7158 following the removal of duplicates. After title and abstract screening, the full texts of 73 articles were completed. Twenty-nine articles were then excluded due to being a secondary analysis (n=17), analysis of a main outcome not relevant to the present study (n=4), or inadequate study design (n=8). Therefore, 44 (41 RCTs and 3 meta-analyses) publications were included in the present analysis ([Figure 1](#f0001){ref-type="fig"}).[@cit0018]--[@cit0061] Of these 44 studies, 36 (82%) were of higher impact factor (IF≥3), and 31 (70%) were assigned a study quality score of 2. Fourteen (32%) received industry funding, five (11%) had an author who was an industry employee, and 17 (39%) had an author(s) with a potential COI. [Table 2](#t0002){ref-type="table"} outlines characteristics of the included studies.Table 2Summary of Full-Text Study AssessmentsArticleImpact FactorStudy QualitySample SizeInterventionsMOM(s)MOM (p\<0.05)?Correspondence?Any COIIndustry AuthorIndustry SponsorSponsorCommentsHIGHER-IMPACT JOURNALS (Impact Factor ≥ 3.0)Heng et al (2016)[@cit0018]3.806280Macular Laser ± IV DEX ImplantBCVANoYesCOI PresentNoYesAllerganSmall sample sizeShah et al (2016)[@cit0019]3.7250IVB vs IV DEX implantBCVA and CSTYesYesCOI PresentNoYesAllerganFailed to mention steroid-related IOP elevation rate, Small sample sizeMaturi et al (2015)[@cit0020]3.7240IVB± IV DEX ImplantBCVA and CSTYesYesCOI PresentNoYesAllerganSmall sample sizeGillies et al (2014)[@cit0021]8.2288IV DEX Implant vs IVBBCVANoYesCOI Not PresentNoYesAllerganFailed to mention steroid-related IOP elevation rate, Small sample sizeCallanan et al (2013)[@cit0022]8.22253Laser ± IV DEX ImplantBCVANoYesCOI PresentYesYesAllergan-Elman et al (2010)[@cit0023]8.22854Laser ± IVR or IVTBCVANoYesCOI PresentNoYesGenentech, Allergan-Ip et al (2008)[@cit0024]8.22840IVT vs Focal/Grid LaserBCVAYesYesCOI PresentNoYesAllergan-Chew et al (2007)[@cit0025]8.22129STT ± Focal LaserBCVA and CSTNoYesCOI PresentNoNoSoley Non-Industry-Googe et al (2011)[@cit0026]3.72345IVR vs IVTBCVA and CSTYesYesCOI PresentNoYesGenentech, Allergan-Campochiaro et al (2012)[@cit0027]8.21953Fluocinolone Vitreous InsertsBCVAYesYesCOI PresentYesYesAlimera Sciences-Pearson et al (2011)[@cit0028]8.21196IV Fluocinolone ImplantBCVAYesYesCOI PresentYesYesBausch & Lomb-Elbendary et al (2011)[@cit0029]3.7232IV Diclofenac vs IVTVA, CMT, IOPNoYesCOI Not PresentNoNoNoneSmall sample sizeCampochiaro et al (2011)[@cit0030]8.21953Low vs High dose Fluocinolone IV ImplantBCVAYesYesCOI PresentYesYesAlimera Sciences-Gillies et al (2011)[@cit0031]8.2184Laser ± IVTBCVAYesYesCOI Not PresentNoNoSoley Non-IndustrySmall sample sizeTakata et al (2010)[@cit0032]3.7224IV vs ST infusion of TriamcinoloneBCVA, CMT, IOPYesYesCOI Not PresentNoNoSoley Non-IndustrySmall sample sizeMirshahi et al (2010)[@cit0033]3.7236PRP and MPC ± IVTBCVA, CMTNoYesNo Disclosure ProvidedNoNoNoneSmall sample sizeGillies et al (2010)[@cit0034]3.38181IVTBCVANoYesCOI Not PresentNoNoSoley Non-IndustrySmall sample sizeSoheilian et al (2009)[@cit0035]8.21150IVB ± IVT vs Macular LaserBCVAYesYesCOI Not PresentNoNoSoley Non-Industry-Maia et al (2009)[@cit0036]5.052244Laser ± IVTBCVA, CMT, TMVYesYesCOI Not PresentNoNoSoley Non-IndustrySmall sample sizeHauser et al (2008)[@cit0037]3.7242IVTBCVA, CMT, IOP, CataractNoYesCOI Not PresentNoNoNoneSmall sample sizeOckrim et al (2008)[@cit0038]3.806288IVT vs LaserBCVANoYesCOI Not PresentNoNoSoley Non-IndustrySmall sample sizePaccola et al (2008)[@cit0039]3.806226IVT vs IVBBCVA and CMTYesYesCOI Not PresentNoNoSoley Non-IndustryFailed to mention steroid-related IOP elevation rate, Small sample sizeSoheilian et al (2007)[@cit0040]3.71103IVB ± IVT vs Macular LaserBCVAYesYesCOI Not PresentNoNoSoley Non-Industry-Lam et al (2007)a[@cit0041]8.22111IVT vs Grid LaserBCVA, CFTNoNoNo Disclosure ProvidedNoNoSoley Non-IndustryLaser alone had similar BCVA and CFT outcomes at final follow up; Failure to mention steroid-related IOP elevation rateLam et al (2007)b[@cit0042]3.806263IVTBCVA, CFT, IOPYesNoCOI Not PresentNoNoSoley Non-IndustryFailed to mention high rates of steroid-related IOP elevations. Small sample sizeAudren et al (2006)[@cit0043]5.052232IVTCMTNoYesNo Disclosure ProvidedNoNoNoneFailed to mention high rates of steroid-related IOP elevations, Small sample sizeBonini-Filho et al (2005)[@cit0044]3.38228STT vs IVTBCVA, CMT, IOP, Lens StatusYesYesCOI Not PresentNoNoSoley Non-IndustrySmall sample sizeSpandau et al (2005)[@cit0045]3.806227IVTBCVA, IOPYesYesCOI Not PresentNoNoNoneSmall sample sizeCardillo et al (2005)[@cit0046]8.2224IVT vs STTBCVA, CMTYesYesCOI Not PresentNoNoSoley Non-IndustrySmall sample sizeTunc et al (2005)[@cit0047]8.2260Focal Laser ± STTBCVAYesYesCOI Not PresentNoNoNoneSmall sample sizeMaturi et al (2018)[@cit0048]5.62129IVR ± IV DEX ImplantBCVANoYesCOI PresentNoYesGenentech, Allergan-Sarao et al (2017)[@cit0049]3.157242PRN vs Single IV DEX ImplantBCVAYesYesCOI PresentNoNoNoneSmall sample sizeIsaac et al (2012)[@cit0050]3.157122IVT vs IVBCFTYesYesNo Disclosure ProvidedNoNoNoneSmall sample sizeKim et al (2008)a[@cit0051]3.7233IVTBCVANoYesNo Disclosure ProvidedNoNoSoley Non-IndustryFailed to mention high rates of steroid-related IOP elevations, Small sample sizeSutter et al (2004)[@cit0052]8.2169IVTBCVAYesNoCOI PresentNoNoSoley Non-IndustryInfectious endophthalmitis developed in one IVT eye, Small sample sizeYilmaz et al (2009)[@cit0053]8.21293IVT vs STTBCVANoYesCOI Not PresentNoNoNoneMeta-AnalysisLOWER-IMPACT JOURNALS (Impact Factor ≥ 2.0 and \< 3.0)Callanan et al (2017)[@cit0054]2.3492363IV DEX implant vs IVRBCVAYesYesCOI PresentYesYesAllergan-Ramu et al (2015)[@cit0055]2.2752100PRN vs fixed dosing IV DEX ImplantBCVANoYesCOI PresentNoYesAllergan-Kriechbaum et al (2014)[@cit0056]2.275230IVB vs IVTBCVA and CSTYesYesCOI PresentNoNoNoneSmall sample sizeZhang et al (2013)[@cit0057]2.2381434IVT vs IVBBCVA and CMTYesYesCOI Not PresentNoNoSoley Non-IndustryMeta-AnalysisDoi et al (2012)[@cit0058]2.349240PPV vs IVTBCVA and CMTYesYesCOI Not PresentNoNoSoley Non-IndustrySmall sample sizeAhmadieh et al (2008)[@cit0059]2.3491115IVB ± IVTCMTNoYesCOI Not PresentNoNoSoley Non-Industry-Qi et al (2012)[@cit0060]2.2381172IVT vs STTBCVA, CMT, IOPNoYesCOI Not PresentNoNoNoneMeta-AnalysisKim et al (2008)b[@cit0061]2.68246STTVA+CMT+DR progressionYesYesCOI Not PresentNoNoNoneSmall sample size[^2]

Correspondence Between Main Outcome Measure and Abstract Conclusion {#s0003-s2001}
-------------------------------------------------------------------

Statistically significant main outcome measures were present in 26 of 44 (59%) of the included studies. There was correspondence between wording of abstract conclusions and study results in 41 of 44 (93%) articles. Reasons for non-correspondence included the failure to mention high rates of steroid-related intraocular pressure (IOP) elevation (n=2)[@cit0041],[@cit0042] and the implication of safety despite a case of endophthalmitis in a small sample (n=1) ([Table 2](#t0002){ref-type="table"}).[@cit0052]

Funding {#s0003-s2002}
-------

Among the 14 studies that received industry funding, two were funded by Alimera Sciences, Inc.,[@cit0027],[@cit0030] eight studies by Allergan, Inc.,[@cit0018]--[@cit0022],[@cit0024],[@cit0054],[@cit0055] three by both Allergan, Inc. and Genentech, Inc.,[@cit0023],[@cit0026],[@cit0048] and one study was funded by Bausch & Lomb, Inc.[@cit0028] Eighteen studies received funding from a nonindustry sponsor.

Comparing Industry-Funded versus Nonindustry-Funded Studies {#s0003-s2003}
-----------------------------------------------------------

A statistically significant main outcome measure was reported in 8 of 14 (57%) industry-funded studies and in 18 of 30 (60%) nonindustry-funded studies (p=1.00, Fisher exact test). Correspondence between abstract conclusions and significance of main outcome was present in 14 of 14 (100%) industry-funded and 27 of 30 (90%) nonindustry-funded studies. The odds ratio of industry funding being associated with noncorrespondence was 0.27 (95% CI: 0.01 to 5.61, p=0.54). Industry-funded studies had significantly greater sample sizes (p=0.01), but similar mean study quality (p=0.50) and journal impact factor (p=0.14) when compared to the nonindustry-funded studies. These data are summarized in [Table 3](#t0003){ref-type="table"}.Table 3Summary of Studies Investigating Steroid Therapy for Diabetic Macular Edema, Based on Funding StatusOutcome StudiedIndustry-Funded (n=14)Nonindustry-Funded (n=30)p-valueCorrespondence of main outcome and conclusions14 (100%)27 (90%)0.54\*Statistically significant (p\<0.05) main outcome8 (57%)18 (60%)1.00\*Sample size, mean ± SD (95% CI)374.6 ± 360.0 (278.4--470.8)82.7 ± 88.3 (66.6--98.8)0.01^†^Study quality, mean ± SD (95% CI)1.79 ± 0.43 (1.68--1.90)1.67 ± 0.48 (1.58--1.76)0.50^‡^Journal impact factor, mean ± SD (95% CI)5.90 ± 2.51 (5.23--6.57)4.68 ± 2.27 (4.27--5.09)0.14^‡^[^3][^4]

Comparing Higher-Impact versus Lower-Impact Publications {#s0003-s2004}
--------------------------------------------------------

When publications were stratified by journal IF into a "high-impact" group (n = 36) with IF ≥ 3 and a "low-impact" group (n=8) with IF\<3, statistically significant main outcome measures were reported in 21 of 36 (58%) high-impact publications and in 5 of 8 (63%) of low-impact publications (p=1.00). Correspondence between abstract conclusions and significance of the main outcome was present in 33 of 36 (92%) high-impact publications and in 8 of 8 (100%) of low-impact publications (p=1.00). When comparing high-impact and low-impact publications there were no significant differences in rates of significant main outcome measures (p=1.00), rates of industry funding (p=1.00), rates of author COI (p=0.76), sample size (p=0.87), or study quality (p=0.68). These data are summarized in [Table 4](#t0004){ref-type="table"}.Table 4Summary of Studies Investigating Steroid Therapy for Diabetic Macular Edema, Based on Impact FactorOutcome StudiedHigh-Impact (n=36)Low-Impact (n=8)p-valueCorrespondence of main outcome and conclusions33 (92%)8 (100%)1.00\*Statistically significant (p \< 0.05) main outcome21 (58%)5 (63%)1.00\*Industry funding12 (33%)2 (25%)1.00\*Any author COI14 (39%)3 (38%)0.76\*Sample size, mean ± SD (95% CI)178.4 ± 270.3 (133.4--223.4)162.5 ± 154.1 (108.0--217.0)0.87^†^Study quality, mean ± SD (95% CI)1.72 ± 0.45 (1.64--1.80)1.63 ± 0.52 (1.45--1.81)0.63^‡^Journal impact factor, mean ± SD (95% CI)5.67 ± 2.21 (5.30--6.04)2.34 ± 0.14 (2.29--2.39)\<0.01^‡^[^5][^6]

Comparing COI-Present versus COI-Absent Publications {#s0003-s2005}
----------------------------------------------------

After compiling responses from corresponding authors with published disclosures, 17 studies had a COI, 22 had no COI and five did not have a disclosure statement. Correspondence between abstract conclusions and significance of main outcome was present in 16 of 17 (94%) studies with a COI, 21 of 22 (96%) studies without a COI and in four of five (80%) studies without a COI disclosure statement (p=0.48). Studies with a COI had a significantly greater mean sample size when compared to studies without a COI or a disclosure statement (p\<0.01). There were no significant differences in rates of significant main outcome measures (p=0.25), study quality (p=0.61), or journal impact factor (p=0.61). These data are summarized in [Table 5](#t0005){ref-type="table"}.Table 5Summary of Studies Investigating Steroid Therapy for Diabetic Macular Edema, Based on Any Author COIOutcome StudiedAuthor COI Present (n=17)No Author COI (n=22)No COI Disclosure (n=5)p-valueCorrespondence of main outcome and conclusions16 (94%)21 (96%)4 (80%)0.48\*Statistically significant (p\<0.05) main outcome11 (65%)14 (64%)1 (20%)0.25\*Sample size, mean ± SD (95% CI)319.2 ± 347.7 (263.7--374.7)93.8 ± 98.8 (45.0--142.6)46.8 ± 36.3 (−55.5--149.1)\<0.01^†^Study quality, mean ± SD (95% CI)1.76 ± 0.44 (1.65--1.87)1.64 ± 0.49 (1.54--1.74)1.80 ±0.45 (1.6--2.0)0.61^‡^Journal impact factor, mean ± SD (95% CI)5.66 ± 2.58 (5.08--6.24)4.68 ± 2.30 (4.17--5.19)4.76 ± 2.05 (3.69--5.83)0.61^‡^[^7][^8]

Discussion {#s0004}
==========

This study aimed to examine whether the presence of industry funding affected the likelihood of biased outcome reporting among studies of intravitreal corticosteroid therapy for DME. Overall, the results of the present study indicated that abstract outcome reporting corresponded with their statistical results for almost all of the included studies, and that funding source was not a predictor for biased reporting. Journal impact factor and the presence of a COI were not predictors of biased outcome reporting. Industry-funded studies and studies with a COI had greater samples sizes but were of similar impact and quality when compared to their counterparts.

The results of this study are reassuring given that biased outcome reporting has been identified in a number of published studies. In 2009, Berwanger et al published the results of a systematic survey of RCT abstract reporting in high-impact general medical journals and found that 29% of studies lacked a definition of the primary outcome and that half of the studies did not report on side effects or harms.[@cit0062] In RCTs of wound treatments, Lockyer et al found that among studies of wound care treatment that did not have a statistically significant result, 71% had some form of biased reporting.[@cit0063] Among RCTs in oncology, Vera-Badillo et al found biased reporting of efficacy outcomes to be common in studies with a negative primary endpoint and that toxicity was underreported.[@cit0064] Recently, biased outcome reported has been shown to be prevalent among high-impact neurology journals.[@cit0065]

Although biased outcome reporting has been identified as a concern in biomedical research, the role of industry sponsorship has been debated in the literature. Recently, a meta-analysis of "spin" in the medical literature found that clinical trials had the greatest variability in the prevalence of spin, with common practices being detracting from statistically nonsignificant results and inappropriately using causal language.[@cit0066] Although the industry sponsorship was hypothesized by the authors to be associated with spin, the results of this meta-analysis were inconclusive.[@cit0066] Published reviews have found that industry funding was not associated with biased reporting among oncology trials,[@cit0067] musculoskeletal studies,[@cit0068] general medical journals,[@cit0069] or in gastrointestinal research.[@cit0070]

Within the ophthalmic literature, Alasbali et al investigated whether funding source was associated with biased abstract conclusions among studies of topical prostaglandins for intraocular pressure lowering.[@cit0009] Their study found 62% of industry-funded articles to have an abstract conclusion that was not consistent with the results of the main outcome measure, while none of the non-industry-funded articles had noncorrespondence. Additionally, while only 24% of the industry-funded studies had a statistically significant main outcome measure, 90% of the industry-funded studies had a proindustry abstract conclusion.[@cit0009] These findings contrast those of the present study quite dramatically and may reflect differences in intervention efficacy (topical prostaglandins vs intravitreal corticosteroids) or differences in methodologies between the studies. Namely, the present study only included RCTs and meta-analyses published in relatively higher-impact journals, which may explain the difference in non-correspondence rates. Recently, our group published a study using a very similar methodology examining the effect of funding source on reporting bias in studies of intravitreal anti-VEGF therapy for retinal vein occlusion.[@cit0010] Similar to the present study, rates of biased abstract reporting were low and were unaffected by funding source, reflecting no differences despite the increased risk profile of intraocular corticosteroids compared to intravitreal anti-VEGF therapy. Finally, the rigorousness of the peer-reviewed process between 2009 and 2019 may partly explain the difference in results. It is interesting to note that all 3 studies with non-correspondence were published prior to 2008.

Although the present study found an overall abstract conclusion and study results correspondence rate of 93%, it is important to note that only the primary outcome was evaluated. The most common primary outcomes among the included studies were visual acuity and retinal thickness. Adverse events, namely intraocular pressure elevation, were rarely reported as a primary outcome and are especially relevant in the context of intravitreal steroid therapy. This review identified seven studies that failed to mention the increased prevalence of steroid-related intraocular pressure elevations in their respective abstracts. If this adverse effect was included as reported as a primary outcome in these studies, the overall non-correspondence rate of the present review would have increased by roughly 11%. This highlights the importance of comprehensive outcome reporting to allow readers to fully understand and appreciate the risks and benefits of therapies they later offer to their patients.

The major limitation of the present study was its highly selective inclusion criteria. Unlike prior studies, the present study only included RCTs and meta-analyses that were published in journals with an impact factor greater than 2. RCTs and meta-analyses are considered to provide the highest level of evidence and are likely preferentially assessed by physicians. Although the present study may have excluded high-quality studies published in journals of lower impact, the authors feel that this analysis captured articles that would more likely be read by physicians when scanning the recent medical literature. Although the present study did not identify differences in the rates of noncorrespondence between the subgroups of journal impact factor, future studies may find it useful to examine biased reporting among studies published in lower-impact journals (impact factor \<2). Nonetheless, it is reassuring to note that among these higher-impact publications of intravitreal corticosteroid therapy for DME, biased abstract reporting overall appears to be uncommon and unrelated to industry sponsorship or authorship, or to journal impact factor.

The data presented in this manuscript were presented in part at the 2019 Annual Meeting of the American Society of Retina Specialists in Chicago, Illinois.
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[^1]: **Abbreviation:** RCT, randomized controlled trial.

[^2]: **Abbreviations:** MOM, main outcome measure; COI, conflict of interest; IV DEX, intravitreal dexamethasone; IVB, intravitreal bevacizumab; IVR, intravitreal ranibizumab; IVT, intravitreal triamcinolone; STT, subtenon triamcinolone; PRP, panretinal photocoagulation; MPC, macular photocoagulation; PRN, pro re nata; BCVA, best corrected visual acuity; CST, central sub-foveal thickness; CMT, central macular thickness; IOP, intraocular pressure; TMV, total macular volume; CFT, central foveal thickness.

[^3]: **Notes:** \*Fisher exact test; ^†^Student's *t*-test; ^‡^Mann--Whitney *U*-test.

[^4]: **Abbreviations:** 95% CI, 95% confidence interval; SD, standard deviation.

[^5]: **Notes:** \*Fisher exact test; ^†^Student's *t*-test; ^‡^Mann--Whitney *U*-test.

[^6]: **Abbreviations:** 95% CI, 95% confidence interval; SD, standard deviation.

[^7]: **Notes:** \*Fisher exact test; ^†^One-way ANOVA; ^‡^Kruskal--Wallis test.

[^8]: **Abbreviations:** 95% CI, 95% confidence interval; SD, standard deviation.
